Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $306.00

Krystal Biotech (NASDAQ:KRYS) had its price objective raised by TD Cowen from $202.00 to $306.00 in a research report released on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Several other research analysts have also recently issued reports on KRYS. Guggenheim set a $224.00 price target on Krystal Biotech and gave the company a “buy” rating in a report on Friday, October 17th. Chardan Capital upped their target price on Krystal Biotech from $216.00 to $220.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. HC Wainwright reiterated a “buy” rating and issued a $310.00 price target (up previously from $240.00) on shares of Krystal Biotech in a research report on Friday. Weiss Ratings restated a “hold (c+)” rating on shares of Krystal Biotech in a report on Monday, December 29th. Finally, Bank of America upped their price objective on shares of Krystal Biotech from $182.00 to $255.00 and gave the company a “buy” rating in a research note on Friday, October 17th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $260.50.

Krystal Biotech Trading Up 5.0%

Shares of Krystal Biotech stock opened at $261.41 on Friday. The company’s 50-day moving average price is $227.55 and its two-hundred day moving average price is $182.91. Krystal Biotech has a 52 week low of $122.80 and a 52 week high of $267.48. The stock has a market cap of $7.58 billion, a PE ratio of 39.19 and a beta of 0.46.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, November 3rd. The company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $1.12 by $1.54. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. The company had revenue of $97.80 million during the quarter, compared to analyst estimates of $93.72 million. On average, equities analysts predict that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the transaction, the insider owned 1,413,711 shares of the company’s stock, valued at $311,242,613.76. The trade was a 1.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 13.70% of the stock is currently owned by company insiders.

Institutional Trading of Krystal Biotech

Several institutional investors have recently made changes to their positions in the stock. Sound View Wealth Advisors Group LLC grew its position in Krystal Biotech by 2.9% during the third quarter. Sound View Wealth Advisors Group LLC now owns 2,003 shares of the company’s stock valued at $354,000 after purchasing an additional 56 shares in the last quarter. Bellevue Group AG boosted its stake in shares of Krystal Biotech by 5.0% during the 3rd quarter. Bellevue Group AG now owns 1,312 shares of the company’s stock valued at $232,000 after buying an additional 62 shares during the period. Bessemer Group Inc. grew its holdings in shares of Krystal Biotech by 106.9% during the 3rd quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock valued at $26,000 after acquiring an additional 77 shares in the last quarter. Arizona State Retirement System grew its holdings in shares of Krystal Biotech by 1.3% during the 3rd quarter. Arizona State Retirement System now owns 6,397 shares of the company’s stock valued at $1,129,000 after acquiring an additional 81 shares in the last quarter. Finally, Main Management ETF Advisors LLC increased its stake in shares of Krystal Biotech by 1.7% in the second quarter. Main Management ETF Advisors LLC now owns 5,131 shares of the company’s stock worth $705,000 after acquiring an additional 84 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Krystal Biotech

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: TD Cowen raised its price target sharply to $306 and maintained a Buy rating — a meaningful analyst upgrade that implies notable upside and likely helped buying interest. TD Cowen Price Target Raise (Benzinga)
• Positive Sentiment: Zacks upgraded KRYS from Hold to Strong Buy, adding another broker endorsement that can boost demand among momentum and quant-driven investors. Zacks Upgrade
• Positive Sentiment: Krystal released a positive interim clinical update for KB407 (Phase 1 CORAL‑1), confirming delivery of wild‑type CFTR to patients’ lungs — a direct biological proof‑of‑concept that materially de‑risks the cystic fibrosis program and is a near‑term clinical catalyst. Business Insider: Positive KB407 Interim Update
• Positive Sentiment: Transcript coverage and management commentary on next steps for KB407 (CORAL‑1) give investors more detail on timing and development plans, helping validate the clinical readout and near‑term milestones. Seeking Alpha: KB407 Transcript
• Neutral Sentiment: Momentum screens and analyst commentary note KRYS’s strong price trend and recent 12‑month outperformance, which can amplify moves but also raises attention to valuation (KRYS has a high P/E relative to later‑stage peers). Zacks: Recent Price Trend

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.